NCT01244620View on ClinicalTrials.gov

A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses

PHASE1TerminatedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

sitaxentan

sitaxsentan 100 mg QD for 6 days

DRUG

tadalafil

tadalafil 40 mg QD for 6 days

DRUG

sitaxsentan

sitaxsentan 100 mg QD for 6 days

DRUG

tadalafil

tadalafil 40 mg QD for 6 days

DRUG

sitaxsentan

sitaxentan 100 mg QD for 6 days

DRUG

sildenafil

sildenafil 20 mg TID for 6 days

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT01244620 - A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses | Biotech Hunter | Biotech Hunter